Want to see HUMA full AI Analyst Report?
Humacyte (HUMA) AI Stock Analysis
Humacyte
(NASDAQ:HUMA)
Overall score is constrained primarily by weak financial performance (large ongoing losses, heavy cash burn, and leverage) and bearish technical positioning (price below all key moving averages with negative MACD). These are partially offset by a more positive earnings-call backdrop driven by clear regulatory milestones and encouraging interim clinical results, but current commercialization scale and cost pressures remain meaningful headwinds.
Humacyte (HUMA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $122.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 6.56M
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 3.21
- Revenue Growth
- 159.29%
- EPS Growth
- -7.39%
- Country
- US
- Employees
- 184
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Humacyte Business Overview & Revenue Model
Company Description
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomica...
Humacyte Earnings Call Summary
The call conveyed strong clinical and regulatory momentum (statistically significant V012 results, planned sBLA filing, IND acceptance for CTEV, commercial team overhaul and early commercial traction) which are material positives. However, near-term financials showed modest absolute sales, rising COGS and inventory reserves, a substantial six‑month loss driven by non-cash liability remeasurements, and continued operating spend. The operational and clinical progress appears to materially outweigh the current financial headwinds, which management is positioning to address as commercialization scales.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company provided clear near‑term guidance and milestones: it plans to file a supplemental BLA for ATEV (Symvess) in November 2026 and will request priority review (RMAT in place) with an expected PDUFA in May 2027 and a targeted commercial launch in late Q2 2027; the V012 Phase III interim (first 80 patients) showed ATEV delivered 91 more catheter‑free days than AV fistula (p=0.0007) and infection rates of 6 vs. 23 per 100 patient‑years, supporting the filing; the FDA accepted an IND for CTEV with a Phase IIa ~10‑patient study to start this quarter (commercial‑scale CTEV lots already produced, batch size ~100); commercial traction is improving with ~$0.4M in Q2 2026 and $0.9M YTD sales, ~20 major U.S. health systems in process to adopt Symvess in H2, an Israel MAA accepted for 180 days, and DoD appropriations support; financials include cash of $80.1M (6/30/26), Q2 cost of goods $1.2M ($0.7M inventory reserve), six‑month COGS $3.3M (including $2.3M reserve), R&D ~$18.1M in Q2 and $37.6M YTD, SG&A $8.0M Q2/$16.0M YTD, other net expense $9.8M Q2 ($1.5M other net income YTD), net loss $36.8M Q2/$54.4M YTD, and $29.4M net cash provided in the first six months of 2026 (vs. $6.9M used in H1 2025).
Humacyte Financial Statement Overview
Summary
Financial profile is weak: TTM revenue is small (~$2.1M) while profitability and cash generation are deeply negative (TTM net income about -$96.7M; operating cash flow about -$97.2M and free cash flow about -$97.6M). Balance sheet risk is elevated with meaningful leverage (TTM debt ~$66.2M vs equity ~$31.3M; ~2.1x debt-to-equity) and volatile equity levels in recent years.
Income Statement
18Very NegativeBalance Sheet
28NegativeCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.12M | 2.04M | 0 | 0 | 1.56M | 1.26M |
| Gross Profit | -14.14M | -15.01M | -7.19M | -76.55M | -6.69M | -60.08M |
| EBITDA | -79.21M | -22.24M | -132.23M | -96.46M | 2.44M | -13.89M |
| Net Income | -96.73M | -40.83M | -148.70M | -110.78M | -11.96M | -26.48M |
Balance Sheet | ||||||
| Total Assets | 138.09M | 116.37M | 137.87M | 128.22M | 204.30M | 286.53M |
| Cash, Cash Equivalents and Short-Term Investments | 79.90M | 50.50M | 44.94M | 80.45M | 151.88M | 225.50M |
| Total Debt | 66.18M | 64.85M | 16.54M | 57.45M | 50.07M | 51.18M |
| Total Liabilities | 106.83M | 113.26M | 190.54M | 114.68M | 87.37M | 164.36M |
| Stockholders Equity | 31.26M | 3.11M | -52.67M | 13.55M | 116.93M | 122.17M |
Cash Flow | ||||||
| Free Cash Flow | -97.56M | -105.93M | -99.69M | -75.58M | -72.18M | -81.41M |
| Operating Cash Flow | -97.19M | -105.04M | -98.12M | -73.31M | -71.13M | -81.19M |
| Investing Cash Flow | -367.00K | -884.00K | -1.57M | -173.00K | 4.84M | -8.22M |
| Financing Cash Flow | 89.43M | 61.49M | 114.18M | 4.51M | -1.45M | 266.98M |
Humacyte Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HUMA, the sentiment is Neutral. The current price of 0.44 is above the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.51, and below the 200-day MA of 0.80, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.59 is Neutral, neither overbought nor oversold. The STOCH value of 24.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HUMA.
Humacyte Risk Analysis
Humacyte disclosed 74 risk factors in its most recent earnings report. Humacyte reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskHumacyte Peers Comparison
Overall Rating
PLX77.7Outperform
MXCT58Neutral
BSEM46Neutral- HUMA45Neutral
CELU44Neutral
MDWD42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PLX | 78Outperform | $206.26M | 10.83 | 31.61% | ― | 30.14% | 181.54% |
| MXCT | 58Neutral | $149.65M | -4.37 | -21.01% | ― | -13.15% | 21.12% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BSEM | 46Neutral | $21.66M | -0.69 | -76.13% | ― | -88.74% | -204.26% |
| HUMA | 45Neutral | $110.59M | -0.86 | -938.20% | ― | 159.29% | -7.39% |
| CELU | 44Neutral | $26.04M | -0.46 | 142.25% | ― | -58.14% | 47.25% |
| MDWD | 42Neutral | $174.29M | -8.37 | -47.24% | ― | -40.26% | 39.18% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HUMA | Humacyte | 0.44 | -1.01 | -69.66% | |
| PLX | Protalix Biotherapeutics | 2.61 | 0.23 | 9.66% | |
| MDWD | Mediwound | 13.39 | -4.76 | -26.23% | |
| MXCT | MaxCyte, Inc. | 1.46 | -0.21 | -12.57% | |
| BSEM | BioStem Technologies | 1.15 | -2.95 | -71.95% | |
| CELU | Celularity Inc. | 0.82 | -1.02 | -55.60% |
Humacyte Corporate Events
Humacyte Bolsters Board for Upcoming Commercial Expansion
PositiveOn September 22, 2026, Humacyte appointed life sciences lawyer and former Exact Sciences executive Scott Coward and medical technology veteran Paul Kuznik to its Board of Directors, with Coward serving as a Class I director through 2028 and Kuznik as...
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
NegativeOn July 31, 2026, Humacyte disclosed that Nasdaq notified the company its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days ended July 30, 2026, putting it out of compliance with listing rules. Nas...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026